| Identification | Back Directory | [Name]
Butanoic acid, 2-[[6-[[3'-(aminomethyl)[1,1'-biphenyl]-3-yl]oxy]-3,5-difluoro-2-pyridinyl]oxy]-, hydrochloride (1:1), (2R)- | [CAS]
2629177-12-2 | [Synonyms]
Butanoic acid, 2-[[6-[[3'-(aminomethyl)[1,1'-biphenyl]-3-yl]oxy]-3,5-difluoro-2-pyridinyl]oxy]-, hydrochloride (1:1), (2R)- | [Molecular Formula]
C22H21ClF2N2O4 | [MOL File]
2629177-12-2.mol | [Molecular Weight]
450.87 |
| Hazard Information | Back Directory | [Biological Activity]
ZK824190 hydrochloride is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC50s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively[1].
ZK824190 (2 mg/kg; PO; Rats with EAE model) exhibits a relatively high oral availability and a moderate half time (T1/2=2.8 h)[1]. | [References]
[1]. Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3372-3375. |
|
|